Press coverage about Foundation Medicine (NASDAQ:FMI) has been trending somewhat positive on Thursday, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foundation Medicine earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.082211778467 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- BidaskClub Downgrades Foundation Medicine (FMI) to Hold (americanbankingnews.com)
- Foundation Medicine Inc (FMI) Given Average Recommendation of “Hold” by Analysts (americanbankingnews.com)
- $44.96 Million in Sales Expected for Foundation Medicine Inc (FMI) This Quarter (americanbankingnews.com)
- Price Target Watch on Shares of Foundation Medicine, Inc. (NASDAQ:FMI) – Monroe Reporter (monroereporter.com)
- Foundation Medicine Inc (FMI) Expected to Announce Earnings of -$1.09 Per Share (americanbankingnews.com)
Several equities research analysts recently issued reports on FMI shares. BidaskClub upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research report on Wednesday, December 6th. Wells Fargo restated a “market perform” rating and set a $80.00 price objective (up from $67.00) on shares of Foundation Medicine in a research report on Thursday, March 8th. Finally, Goldman Sachs started coverage on shares of Foundation Medicine in a research report on Monday, January 29th. They set a “neutral” rating and a $73.00 price objective for the company. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $69.60.
Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings data on Wednesday, March 7th. The company reported ($1.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.08). Foundation Medicine had a negative net margin of 105.60% and a negative return on equity of 207.73%. The business had revenue of $48.90 million during the quarter, compared to analysts’ expectations of $48.69 million. During the same period in the previous year, the business posted ($1.02) EPS. The company’s revenue for the quarter was up 69.8% compared to the same quarter last year. analysts forecast that Foundation Medicine will post -4.22 EPS for the current fiscal year.
In related news, insider Vincent A. Miller sold 2,349 shares of Foundation Medicine stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total value of $150,336.00. Following the completion of the transaction, the insider now owns 99,484 shares in the company, valued at $6,366,976. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Robert W. Hesslein sold 1,864 shares of Foundation Medicine stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $64.00, for a total transaction of $119,296.00. The disclosure for this sale can be found here. In the last three months, insiders sold 294,952 shares of company stock valued at $20,147,318. Insiders own 2.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Foundation Medicine (NASDAQ:FMI) Stock Price” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/29/foundation-medicine-fmi-getting-somewhat-favorable-media-coverage-analysis-shows/1970680.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.